Atlas Venture Life Science Advisors, LLC Q4 2024 Filing
Filed February 6, 2025
Portfolio Value
$819.7B
Holdings
13
Report Date
Q4 2024
Filing Type
13F-HR
All Holdings (13 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | KYMRKymera Therapeutics, Inc. | 4,896,462 | $197.0B | 24.03% | |
| 2 | DYNDyne Therapeutics, Inc. | 8,019,354 | $188.9B | 23.05% | |
| 3 | IRONDisc Medicine, Inc. | 2,509,456 | $159.1B | 19.41% | |
| 4 | THRDThird Harmonic Bio, Inc. | 10,402,286 | $107.0B | 13.06% | |
| 5 | DAWNDay One Biopharmaceuticals, Inc. | 6,430,257 | $81.5B | 9.94% | |
| 6 | KRROKorro Bio, Inc. | 1,137,149 | $43.3B | 5.28% | |
| 7 | VIGLVigil Neuroscience, Inc. | 5,836,874 | $9.9B | 1.21% | |
| 8 | GBIOGBXGeneration Bio, Co. | 8,279,484 | $8.8B | 1.07% | |
| 9 | —Ikena Oncology, Inc. | 5,018,178 | $8.2B | 1.00% | |
| 10 | QTTBQ32 Bio, Inc. | 2,092,106 | $7.2B | 0.88% | |
| 11 | AVTEAerovate Therapeutics, Inc. | 1,799,232 | $4.8B | 0.58% | |
| 12 | TECXTectonic Therapeutics, Inc. | 78,447 | $3.6B | 0.44% | |
| 13 | SPROSpero Therapeutics, Inc. | 305,255 | $314.4M | 0.04% |